Genetics & Pathophysiology of Dystrophinopathies

Question	Answer
1. What is the genetic basis and inheritance pattern of Duchenne Muscular Dystrophy (DMD)?	DMD is an X-linked recessive disorder caused by mutations in the DMD gene located on chromosome Xp21.2. The DMD gene is the largest known human gene (spanning 2.4 Mb with 79 exons), making it highly susceptible to spontaneous mutations.
2. What is Haldane's Principle in the context of DMD genetics?	In severe X-linked recessive diseases where affected males do not reproduce (fitness = 0), one-third (33%) of all cases arise from spontaneous de novo mutations, while two-thirds (67%) are inherited from asymptomatic or carrier mothers.
3. What is the "Reading Frame Rule" (Monaco Hypothesis) differentiating DMD from BMD?	Mutations that disrupt the open translational reading frame (out-of-frame deletions/duplications/nonsense mutations) result in premature stop codons and complete absence (<3%) of functional dystrophin protein, leading to severe DMD; in contrast, in-frame mutations maintain the triplet reading frame, generating a truncated but partially functional dystrophin protein (10–40% quantity or abnormal size), causing milder Becker Muscular Dystrophy (BMD).
4. What is the physiological function of the Dystrophin protein?	Dystrophin is a 427-kDa rod-shaped sub-sarcolemmal cytoskeletal protein that links internal F-actin of the muscle cytoskeleton to the extracellular matrix (laminin-2) via the Dystrophin-Associated Glycoprotein Complex (DGC / sarcoglycans, dystroglycans); it acts as a mechanical shock-absorber during muscle contraction, preventing sarcolemmal micro-tears and excessive calcium influx.
5. Can a female ever present with full-blown Duchenne Muscular Dystrophy?	Yes, through 5 rare genetic mechanisms: 1. Turner syndrome (45,X); 2. Unbalanced / Skewed X-inactivation (extreme Lyonization favoring the mutant X chromosome); 3. X-autosome balanced translocation disrupting the DMD gene on Xp21; 4. Uniparental disomy of the X chromosome; 5. Compound heterozygosity (carrier mother married to affected/BMD father).

Clinical Manifestations & Natural History

Question	Answer
1. What is the classical chronological progression of muscle weakness in DMD?	Onset at 2–4 years (pelvic girdle weakness, clumsy gait, difficulty rising from floor) $\rightarrow$ 5–7 years (compensatory waddling gait, lumbar lordosis, calf pseudohypertrophy, Gowers' sign) $\rightarrow$ 8–10 years (loss of stair climbing, frequent falls) $\rightarrow$ 10–13 years (loss of independent ambulation / wheelchair dependency) $\rightarrow$ 15–20+ years (scoliosis, diaphragmatic failure, restrictive lung disease, dilated cardiomyopathy).
2. Why are the calf muscles enlarged in DMD if the muscles are weak?	This is pseudohypertrophy (false hypertrophy). Progressive sarcolemmal breakdown leads to muscle fiber necrosis, chronic inflammation, and extensive proliferation of endomysial fat and connective tissue (fibrofatty replacement), making the calf bulky and rubbery rather than genuinely hypertrophied.
3. What other muscles typically show true hypertrophy or pseudohypertrophy in DMD?	Deltoids, infraspinatus, gluteus medius, quadriceps (early), vastus lateralis, and tongue; in contrast, the sternal head of pectoralis major, latissimus dorsi, and biceps brachii show prominent early wasting.
4. Why do children with DMD have an exaggerated lumbar lordosis when standing?	It is a biomechanical compensation for severe Gluteus Maximus and Quadriceps weakness; the child tilts the pelvis forward (anterior pelvic tilt) and extends the lumbar spine, shifting the body's center of gravity posterior to the hip joints and anterior to the knee joints, mechanically locking the joints in extension during stance without requiring muscular effort.
5. Why is cognitive impairment or speech delay present in ~30% of boys with DMD?	Dystrophin isoforms (such as Dp140 and Dp71) are physiologically expressed in the cerebral cortex, hippocampus, and Purkinje cells of the cerebellum; their deficiency alters central synaptic plasticity and GABAergic receptor clustering, predisposing to developmental language delay, intellectual disability, and ADHD.

Physical Examination & Semiological Maneuvers

Question	Answer
1. Describe the exact elicitation and biomechanical stages of Gowers' sign.	The child is asked to rise from a supine or sitting position on the floor: 1. Child rolls over onto the abdomen (prone position); 2. Rises onto hands and knees (four-point quadrupedal stance); 3. Pushes with feet and hands to extend the knees into a wide-based inverted-V stance; 4. "Climbs up his own legs" by placing hands alternately on the shins, knees, and thighs to push the torso into an upright vertical posture using upper limb power.
2. What is the "Valley Sign" in DMD, and how is it tested?	The child is asked to abduct both shoulders to 90° with elbows flexed: the examiner visualizes a prominent longitudinal depression (the "valley") bounded anteriorly by the hypertrophied anterior axillary fold and posteriorly by the hypertrophied infraspinatus/deltoid muscle mass, created by severe wasting of the axillary and periscapular muscles.
3. Why are Knee Jerks lost early while Ankle Jerks are preserved until late in DMD?	Knee jerk relies on the quadriceps femoris muscle, which undergoes early, severe dystrophic fiber loss and fibrofatty degeneration, abolishing the reflex arc; in contrast, the gastrocnemius-soleus complex retains functional contractile fibers and brisk reflexivity until late in the non-ambulatory stage.
4. How do you elicit the "Trendelenburg Sign" and what does a waddling gait indicate?	When the child stands on one leg, the pelvis on the contralateral unsupported side drops downward due to weakness of the ipsilateral hip abductors (Gluteus Medius and Minimus); bilateral involvement produces an alternating trunk sway known as a Waddling Gait.
5. What is the "Axillary Slipping Maneuver" (Forester-like sign)?	When the examiner places hands under the child's axillae and attempts to lift the child vertically, the child's shoulders elevate passively and the child slips through the examiner's hands due to profound weakness and hypotonia of the pectoral and periscapular girdle muscles.

Diagnostic Workup (Enzymes, Genetics, Muscle Biopsy)

Question	Answer
1. What is the significance of Serum Creatine Kinase (CK) in DMD?	Serum CK is markedly elevated (10,000 to 30,000+ IU/L, >50–100 times normal) from birth, even in the preclinical asymptomatic phase; a normal or minimally elevated CK unequivocally excludes DMD. (Note: In late end-stage disease, CK levels gradually decline as muscle mass is completely replaced by fat).
2. Why are SGOT (AST) and SGPT (ALT) elevated in DMD, and what clinical error does this cause?	Transaminases (AST, ALT) and LDH are abundant in skeletal muscle cytoplasm; muscle membrane breakdown releases them into the bloodstream, frequently leading unsuspecting clinicians to incorrectly diagnose hepatitis or liver disease.
3. What is the gold-standard first-line genetic test for confirming DMD?	Multiplex Ligation-dependent Probe Amplification (MLPA) or chromosomal microarray targeting all 79 exons of the DMD gene, which identifies deletions (60–65%) and duplications (5–10%) and determines whether the mutation disrupts the translational reading frame.
4. If MLPA is negative in a boy with classic DMD symptoms and CK of 25,000 IU/L, what is the next step?	Perform Next Generation Sequencing (NGS) / Whole DMD Gene Sequencing to detect small point mutations (nonsense/stop codons, small insertions/deletions, and splice-site mutations), which account for 25–30% of cases.
5. When is a Muscle Biopsy indicated in the modern era of DMD diagnosis?	Muscle biopsy is no longer required for routine diagnosis; it is reserved strictly for cases where comprehensive genetic testing (MLPA + NGS) is completely negative or inconclusive, or when differentiating DMD from limb-girdle muscular dystrophies or congenital myopathies.
6. What are the classical muscle biopsy and immunohistochemistry findings in DMD?	H&E staining shows marked fiber size variation, necrotic and regenerating muscle fibers, and massive endomysial fibrofatty replacement; Dystrophin Immunohistochemistry and Western Blot show complete absence (<3% of normal) of dystrophin staining on the sarcolemmal membrane.

Corticosteroid Therapy & Disease-Modifying Protocols

Question	Answer
1. What is the current standard of care regarding Corticosteroids in DMD?	Corticosteroids are the only proven disease-modifying pharmacotherapy: they prolong independent ambulation by 2–4 years, maintain upper limb and respiratory muscle strength, decrease the incidence of scoliosis, and delay the onset of cardiomyopathy.
2. What is the recommended starting age and dosing for Deflazacort vs Prednisolone?	Initiate once motor development reaches a plateau or begins declining (usually 4–6 years of age): Deflazacort $0.9\text{ mg/kg/day}$ orally in the morning, OR Prednisolone $0.75\text{ mg/kg/day}$ orally in the morning (maximum 35–40 mg/day).
3. Compare Deflazacort versus Prednisolone in terms of efficacy and side effect profile.	Deflazacort causes significantly less weight gain, lower incidence of behavioral hyperactivity, and provides longer preservation of ambulation, but has a higher risk of asymptomatic posterior subcapsular cataracts and linear growth stunting; Prednisolone is cheaper and widely available, but causes marked weight gain, cushingoid appearance, and behavioral changes.
4. What are the Exon-Skipping therapies approved for DMD, and how do they work?	Synthetic Antisense Oligonucleotides (ASOs) bind to specific pre-mRNA exons during splicing, skipping the mutated exon to restore the translational reading frame and convert a severe out-of-frame DMD mutation into an in-frame, Becker-like truncated dystrophin protein: Eteplirsen (Exon 51), Golodirsen / Viltolarsen (Exon 53), and Casimersen (Exon 45).
5. What is Ataluren, and which subset of DMD patients is eligible?	Ataluren (Translarna) is an oral small-molecule stop-codon readthrough agent that allows the ribosome to bypass premature stop codons (nonsense mutations) during translation, indicated for patients $\ge 2$ years with confirmed nonsense point mutations (~13% of DMD).

Cardiopulmonary & Multidisciplinary Management

Question	Answer
1. What is the nature and timing of cardiac involvement in DMD?	Dystrophin deficiency in cardiomyocytes causes progressive posterobasal and transmural left ventricular myocardial fibrosis, manifesting as Dilated Cardiomyopathy (DCM) and arrhythmias; it is subclinical in early years, present on cardiac MRI/echo in ~50% by 10 years, and universal (>90%) by 14–18 years of age.
2. When should cardioprotective medications be initiated in DMD?	Prophylactic ACE Inhibitors (Enalapril / Lisinopril) or ARBs should be initiated by 10 years of age (even in asymptomatic patients with normal ejection fraction) to slow the progression of myocardial fibrosis and ventricular remodeling.
3. What type of respiratory failure occurs in DMD, and how is it monitored?	Type 2 (Hypercapnic) Restrictive Respiratory Failure due to progressive diaphragmatic, intercostal, and abdominal wall muscle weakness; monitored by serial upright and supine Forced Vital Capacity (FVC) and nocturnal pulse oximetry / capnography.
4. What is the indication for Nocturnal Non-Invasive Ventilation (NIV / BiPAP)?	Symptoms of nocturnal hypoventilation (morning headaches, daytime somnolence, nocturnal awakenings), baseline FVC $<50\%$ of predicted, or overnight SpO₂ $<95\%$ / transcutaneous $PCO_2 >45\text{ mmHg}$.
5. What types of physical therapy exercises should be STRICTLY AVOIDED in DMD?	Strenuous eccentric resistance exercises (e.g., downhill running, trampolining, heavy weight-lifting); eccentric contractions stretch active muscle fibers, generating massive sarcolemmal stress and accelerating muscle fiber necrosis and rhabdomyolysis in dystrophin-deficient muscle.

High-Yield VIVA TRAPs & Counter-Questions

Question	Answer
1. VIVA TRAP: The examiner asks: "Is Gowers' sign pathognomonic for Duchenne Muscular Dystrophy?"	NO. Gowers' sign is a semiological sign of severe proximal hip extensor (gluteus maximus) and quadriceps weakness of any etiology; it is seen in Spinal Muscular Atrophy, Becker Muscular Dystrophy, Limb-Girdle Muscular Dystrophies, Polymyositis, Congenital Myopathies, and juvenile Pompe disease. It is most classic in DMD simply because of its prevalence.
2. VIVA TRAP: Examiner counter-question: "A 4-year-old child with elevated AST/ALT is referred for suspected chronic hepatitis. The liver ultrasound is normal. What is the next test?"	Serum Creatine Kinase (CK). Transaminases (AST, ALT) are abundant in muscle; unsuspected muscular dystrophies frequently present with asymptomatic 'transaminitis' before overt motor symptoms emerge, leading to unnecessary liver biopsies if CK is not checked.
3. VIVA TRAP: "A female child presents with classical proximal weakness, calf pseudohypertrophy, Gowers' sign, and CK of 20,000 IU/L. How is this possible?"	1. Turner syndrome (45,X0) with a single maternally inherited mutated X chromosome; 2. Skewed / Non-random Lyonization in a carrier female; 3. X-Autosome translocation involving Xp21; 4. Autosomal Recessive Limb-Girdle Muscular Dystrophy (Sarcoglycanopathy / LGMD R3-R6), which closely mimics DMD clinically.
4. VIVA TRAP: "Why does a boy with DMD walk on his toes (equinus gait) before developing fixed ankle contractures?"	Early toe-walking is a dynamic compensatory biomechanical mechanism to stabilize the knee: placing the forefoot on the ground moves the ground reaction force vector anterior to the knee joint axis, creating an extensor moment that prevents the knee from buckling despite weak quadriceps. Fixed Achilles tendon contractures develop secondarily later.
5. VIVA TRAP: "Should you perform an EMG / Nerve Conduction Study in a child with suspected DMD before ordering genetic testing?"	NO. Routine EMG and NCS are painful, invasive, unnecessary, and discouraged by international DMD care guidelines. When high clinical suspicion and elevated CK exist, proceed straight to MLPA genetic testing.
6. VIVA TRAP: "If a mother of a boy with DMD is tested by MLPA and her blood DNA shows NO mutation, can you reassure her that future pregnancies have 0% risk?"	NO. She still faces a 15–20% recurrence risk due to Germline (Gonadal) Mosaicism (the mutation is present in a fraction of her oocytes despite being undetectable in her peripheral blood leukocytes). Prenatal diagnostic testing via chorionic villus sampling (CVS) remains mandatory for all future pregnancies.